- Exact Sciences Corp. (EXAS, Financial) to present 15 abstracts at Digestive Disease Week (DDW) 2025, highlighting the Cologuard® test.
- Data from over 500,000 patients shows high adherence and strong predicted preference for the Cologuard® test.
- Cologuard® test is positioned as a leading screening option for adults aged 45 and older at average risk for colorectal cancer.
Exact Sciences Corp. (EXAS), a leader in cancer screening and diagnostics, announced plans to present 15 abstracts at the upcoming Digestive Disease Week (DDW) 2025 in San Diego. The presentations will showcase the effectiveness and strong predicted preference for the Cologuard® test, a noninvasive colorectal cancer (CRC) screening tool, grounded in data from over half a million patients.
The DDW event, held from May 3-6, 2025, is a prominent gathering for professionals in gastroenterology, hepatology, GI endoscopy, and gastrointestinal surgery. Exact Sciences' abstracts will be accessible on the DDW website starting May 3, 2025. The Cologuard® test, developed in collaboration with Mayo Clinic, offers adults aged 45 and over an effective CRC screening option by detecting DNA markers and blood in stool.
Paul Limburg, MD, MPH, AGAF, chief medical officer for Screening at Exact Sciences, emphasized the importance of the Cologuard® test in addressing colonoscopy screening capacity constraints and improving CRC detection and prevention. The abstracts also include data on adherence rates for the Cologuard test across various demographics, reinforcing its role in enhancing CRC screening outcomes.
Developed to further improve accuracy, the Cologuard Plus™ test has been FDA-approved and promises to reduce false positives by over 40% compared to the original Cologuard test, minimizing unnecessary follow-ups. Both tests underscore Exact Sciences' commitment to advancing cancer screening initiatives.
